Focused On-demand Library for Actin-binding LIM protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6H8Q1

UPID:

ABLM2_HUMAN

Alternative names:

Actin-binding LIM protein family member 2

Alternative UPACC:

Q6H8Q1; E9PF39; Q08E71; Q19VH0; Q6H8Q0; Q6NX73; Q8N3C5; Q8N9E9; Q8N9G2; Q96JL7

Background:

Actin-binding LIM protein 2, also known as Actin-binding LIM protein family member 2, plays a crucial role in cellular structure and function. It acts as a scaffold protein, facilitating the organization of the actin cytoskeleton, and may stimulate ABRA activity, which in turn enhances ABRA-dependent SRF transcriptional activity. This protein's involvement in the intricate network of cellular signaling underscores its importance in maintaining cellular integrity and function.

Therapeutic significance:

Understanding the role of Actin-binding LIM protein 2 could open doors to potential therapeutic strategies. Its pivotal role in cellular structure and signaling pathways makes it a compelling target for drug discovery, aiming to modulate its activity for therapeutic benefits.